Watchlist
HZO · MarineMax, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
MarineMax’s $53.00-per-share cash merger prices completion of the Safe Harbor transaction on the announced end-2026 timetable. Closing would settle the case; a weekly close below $50, termination or failure to complete by 2026-12-31 would invalidate it.
Kill line
A weekly close below $50 invalidates the merger-completion thesis; transaction termination or failure to complete by 2026-12-31 independently defeats the stated timetable case.
Pick status
Open commitment catalyst in 10dscored if the kill line above fires How this is scored →Latest analysis and events for HZO —
As of 13 September 2026, the latest FrontierPicks analysis for MarineMax, Inc. (HZO): MarineMax’s $53.00-per-share cash merger prices completion of the Safe Harbor transaction on the announced end-2026 timetable. Closing would settle the case; a weekly close below $50, termination or failure to complete by 2026-12-31 would invalidate it.
Kill line: A weekly close below $50 invalidates the merger-completion thesis; transaction termination or failure to complete by 2026-12-31 independently defeats the stated timetable case.
Next dated event on file: — catalyst in 10d.
Current Thesis
MarineMax’s $53.00-per-share cash merger with Safe Harbor remains a completion story, settled by closing on the announced end-2026 timetable before a weekly close below $50 invalidates the case. The consideration and expected timetable come from the companies’ 2026-08-10 announcement. Merger announcement
The September refresh shows price resilience without a verified new transaction milestone: the supplied adjusted market series records a $52.21 close on 2026-09-11, while MarineMax’s news page checked on 2026-09-13 still lists the merger announcement as its latest release. This does not establish that regulatory clearance or a proxy filing has not occurred. Company news
As an interpretation of the dated coverage, the narrative is maturing — the 2026-08-10 agreement is established news, and Benzinga’s supplied 2026-08-21 and 2026-09-03 coverage revisits momentum warnings rather than reporting a new transaction milestone. Completion before the published price threshold is breached remains the high-conviction forecast; that assessment rests on the signed agreement and financing commitment, rather than a measured deal-success frequency.
Bullish and bearish views on MarineMax, Inc.
The model's bull view on MarineMax, Inc. (HZO), in brief: Financing is contractually committed. The 2026-08-10 Form 8-K discloses a Blackstone Infrastructure equity commitment and no financing condition. These support the completion forecast, which fails under the price or transaction conditions below. Merger filing The board supports… The bear view: Regulatory conditions remain substantive. Both cases follow in full.
Bull Case
- Financing is contractually committed. The 2026-08-10 Form 8-K discloses a Blackstone Infrastructure equity commitment and no financing condition. These support the completion forecast, which fails under the price or transaction conditions below. Merger filing
- The board supports defined consideration. The 2026-08-10 announcement records unanimous board approval and $53.00 per share in cash. These are documented transaction terms; shareholder approval remains a separate requirement. Merger announcement
Bear Case
- Regulatory conditions remain substantive. The 2026-08-10 filing requires Hart-Scott-Rodino antitrust clearance and specified foreign approvals. A disclosed regulatory obstacle preventing completion by 2026-12-31 would defeat the timetable thesis. Merger filing
- Standalone results missed reported expectations. The supplied 2026-07-23 results record fiscal third-quarter revenue of $611.258 million against $682.489 million consensus, and adjusted earnings per share of $0.81 against $0.83 consensus. These figures do not establish a standalone valuation; transaction termination would make operating performance central again.
- A firm meeting date is missing. MarineMax’s events page, checked on 2026-09-13, lists no upcoming events. That calendar does not establish a shareholder-vote date or demonstrate a delay. Company events
Setup & Price Structure
The supplied adjusted daily bars show a 2026-09-11 close of $52.21, a 52-week high of $52.46 and a reported distance below that high of 0.5%. The same snapshot records a three-month price increase of 53.6% and a 14-period relative strength index (RSI) of 51.1. The market price remains below the $53.00 contractual consideration announced on 2026-08-10.
Benzinga’s supplied 2026-08-21 and 2026-09-03 articles cluster around overbought-stock warnings. The later 2026-09-11 RSI reading does not support carrying those earlier descriptions forward. The coverage sample is too small to establish crowding, and no current volume, fund-flow, short-interest or moving-average measurements are supplied.
The $50 weekly-close threshold is an analytical thesis-break condition. The available bars do not establish it as a tested support shelf.
Catalyst Calendar (next 30 days)
- 2026-09-30 — Fiscal year-end. MarineMax’s supplied reporting calendar identifies this as the fiscal 2026 year-end, not an earnings-release date. No confirmed merger-resolution event is established for the next 30 days by the available disclosures as of 2026-09-13.
- 2026-12-31 — Announced completion horizon. The 2026-08-10 announcement expects completion by the end of calendar 2026; this is an expectation rather than a scheduled closing appointment. An uncompleted transaction after this date would fail the timetable case. Merger announcement
What Would Change Our Mind
Loss of the merger-price structure would break the case: a weekly close below $50 invalidates the completion forecast at the published market threshold. Transaction termination or failure to complete by 2026-12-31 would independently defeat the stated thesis.
A filed approval announcement and confirmed completion date would strengthen the case by resolving conditions identified in the 2026-08-10 agreement. The scheduled payment itself would settle the completion claim. Merger filing
Correlation Notes
This is a single-name transaction setup. The $53.00 cash consideration announced on 2026-08-10 supplies a company-specific reference, while the 2026-09-11 price snapshot supplies no peer-return series from which to measure sector correlation. Merger announcement
Benzinga grouped MarineMax with other consumer stocks on 2026-08-21 and 2026-09-03, but editorial grouping is not evidence of common price drivers. The available sample supports no claim about consumer-sector participation or changing correlation.
Notes
- Shares delist from the NYSE on completion; the security terminates at $53.00 cash rather than re-rating.
- Merger agreement carries no financing condition; Blackstone Infrastructure provided an equity commitment.
- Company termination fee $31,650,000; no traditional go-shop, only a fiduciary out with one-business-day notice to the buyer.
- Outside date 2027-05-09, with two automatic three-month extensions available for regulatory approvals (15 months maximum).
- MarineMax fiscal year ends September 30; FQ4/FY2026 results normally report in late October.
- Approval requires a majority of votes entitled to be cast, so abstentions count against the deal.
Related · shared themes
APGE
Apogee Therapeutics, Inc.
Apogee Therapeutics’ $135.11-per-share cash-acquisition thesis resolved with AbbVie’s completion on 2026-09-03. The 2026-09-14 Form 15 advances administrative closure, leaving no unresolved APGE acquisition catalyst.
ATAI
AtaiBeckley Inc.
AtaiBeckley's Lilly acquisition thesis resolved with completion on 2026-09-11, ending the pending-merger case. Remaining contingent payments depend on disclosed clinical and regulatory milestones; Nasdaq suspended ATAI effective 2026-09-14.
DSGR
Distribution Solutions Group, Inc.
Distribution Solutions Group’s $35.00 cash acquisition remains a completion thesis, with the minority vote and closing settling the case. HSR clearance occurred on 2026-08-20; a daily close below $33.50 invalidates the price thesis.
ATKR
Atkore Inc.
Atkore's $95.00 cash-merger thesis now turns on the October 7 shareholder vote and remaining approvals after September 14 US antitrust clearance. Completion before a weekly close below $88 constitutes success; termination negates the case.